Clinical Trial Update: HDM201 and Pazopanib in Patients With P53 Wild-type Advanced/Metastatic Soft Tissue Sarcomas [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for HDM201 in combination with pazopanib in patients with P53 wild-type advanced/metastatic soft tissue sarcoma; Phase 1/2, currently not …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Soft Tissue Sarcoma

Drugs mentioned

• HDM201
• Pazopanib (Pazopanib)

Snippet

Sponsor: Centre Leon Berard | Conditions: Advanced Soft-tissue Sarcoma, Metastatic Soft-tissue Sarcoma | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING